Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.6510
+0.0263 (4.21%)
Jul 28, 2026, 10:37 AM EDT - Market open
Aprea Therapeutics Employees
Aprea Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$15,412
Profits / Employee
-$1,494,353
Market Cap
8.06M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - |
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | -2 | -22.22% |
| Dec 31, 2022 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 41 |
| Bolt Biotherapeutics | 23 |
| BioRestorative Therapies | 14 |
| Processa Pharmaceuticals | 12 |
| MetaVia | 8 |
| CNS Pharmaceuticals | 8 |
| Traws Pharma | 7 |
| Immuron | 7 |
APRE News
- 6 weeks ago - Aprea Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors - GlobeNewsWire
- 2 months ago - Aprea Therapeutics price target lowered to $6 from $7 at Wedbush - TheFly
- 2 months ago - Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year - TheFly
- 2 months ago - Aprea Therapeutics Earnings release: Q1 2026 - Filings
- 2 months ago - Aprea Therapeutics Quarterly report: Q1 2026 - Filings
- 2 months ago - Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Aprea Therapeutics initiated with an Outperform at Oppenheimer - TheFly